Le Lézard
Classified in: Science and technology, Business
Subject: PDT

Flash News: OKX to List USDT-Margined ZENT Perpetual Futures Contract


NASSAU, Bahamas, May 9, 2024 /PRNewswire/ -- OKX, a leading crypto exchange and Web3 technology company, has issued updates for May 9, 2024.

OKX to List USDT-Margined ZENT Perpetual Futures Contract

OKX today announced that it will list ZENT on its perpetual futures market, enabling users to long or short ZENT with up to 20x leverage. This listing is scheduled to go live at 8:30 am UTC on May 9, 2024. In conjunction with this, ZENT margin trading and Simple Earn will be enabled at 8:00 am UTC on the same day.

Zentry (ZENT) is the new token for the Zentry gaming universe, which goes beyond a typical Decentralized Autonomous Organization (DAO). Zentry aims to transform lives with its Gaming Superlayer by becoming the foundational layer for the Play Economy. The introduction of ZENT, converted from the original GuildFi token (GF) at a 1-for-10 split, aims to enhance the community's experience and expand the range of utilities within the Zentry ecosystem.

Further details on the new listing are available here.

For more information, please visit the Support Center.

For further information, please contact:
[email protected]

About OKX

OKX is a leading global crypto exchange and innovative Web3 company. Trusted by more than 50 million global users, OKX is known for being one of the fastest and most reliable crypto apps in the world.

To learn more about OKX, download our app or visit: okx.com

Disclaimer

SOURCE OKX


These press releases may also interest you

at 02:46
Flash News: OKX DEX Incorporates ChangeNOW's Cross-Chain Bridges: Empowering the OKX Web3 Community with Simplified Cross-Chain Interactions
OKX, a leading Web3 technology company, has issued updates for May 20, 2024. OKX DEX Incorporates ChangeNOW's Cross-Chain Bridges:...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

at 02:05
Astera Labs Extends Interoperability Leadership Driving Seamless PCIe 6.x Deployment
Astera Labs , a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced expanded PCIe® 6.x testing capabilities in its Cloud-Scale Interop Lab to enable seamless interoperability between Aries 6...

at 02:05
Exchange Solutions Unveils Industry-First Generative AI Feature Enablement for a Loyalty Platform
Exchange Solutions, a leading provider of personalized loyalty solutions, proudly announces the launch of groundbreaking Generative AI features integrated into its loyalty platform. This innovative advancement, now available for use within the SaaS...

More news about Science and technology...


News published on and distributed by: